Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Income from Continuing Operations (2016 - 2025)

Vistagen Therapeutics' Income from Continuing Operations history spans 13 years, with the latest figure at 18899000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 34.14% year-over-year to 18899000.0; the TTM value through Dec 2025 reached 67046000.0, down 85.87%, while the annual FY2025 figure was 51418000.0, 75.12% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 18899000.0 at Vistagen Therapeutics, up from 19417000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1711100.0 in Q1 2024 and bottomed at 19417000.0 in Q3 2025.
  • The 4-year median for Income from Continuing Operations is 10733000.0 (2024), against an average of 10683020.0.
  • The largest YoY upside for Income from Continuing Operations was 34.14% in 2025 against a maximum downside of 896.86% in 2025.
  • A 4-year view of Income from Continuing Operations shows it stood at 10535100.0 in 2021, then soared by 39.73% to 6350000.0 in 2023, then tumbled by 121.87% to 14089000.0 in 2024, then crashed by 34.14% to 18899000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Income from Continuing Operations are 18899000.0 (Q4 2025), 19417000.0 (Q3 2025), and 15095000.0 (Q2 2025).